On May 5, 2016 Medivation, Inc. (NASDAQ:MDVN) reiterating its rejection of Sanofi’s substantially inadequate proposal to acquire the Company for $52.50 per share in cash, following the receipt of a letter from Sanofi (Press release, Medivation, MAY 5, 2016, View Source [SID:1234511986]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Medivation notes that Sanofi’s letter simply restates an inadequate proposal that the Medivation Board of Directors has already determined substantially undervalues the Company, its leading oncology franchise, and innovative late-stage pipeline. Medivation’s Board of Directors believes the execution of Medivation’s business plan will deliver value to its stockholders that is far superior to Sanofi’s proposal. Medivation’s Board will continue to act in the best interest of its stockholders.

As previously announced, the Company will host a live teleconference with management to discuss first quarter 2016 results, followed by a presentation to review the Company’s business performance and future prospects today at 4:30 p.m. Eastern Time.

A press release announcing the first quarter 2016 will be released after markets close on May 5, 2016.

Individuals may access the live audio webcast of the two hour live teleconference and presentation materials by visiting: View Source Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
Interested parties may also listen to the teleconference:
U.S. Dial-in number: 877-303-2523
International Dial-in number: +1-253-237-1755
Conference ID: 95457891
Evercore and J.P. Morgan are serving as financial advisors to Medivation, and Wachtell, Lipton, Rosen & Katz and Cooley LLP are acting as legal counsel.